Literature DB >> 21544042

Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009.

.   

Abstract

Hepatitis C virus (HCV) infection is a major cause of liver disease and hepatocellular carcinoma in the United States. Of the estimated 2.7--3.9 million persons with active HCV infection, most were born during 1945--1964 and likely were infected during the 1970s and 1980s, before the advent of prevention measures. Nationwide, rates of acute, symptomatic HCV infection declined during 1992--2005 and then began to level. Declines also were observed in rates of newly reported HCV infection in Massachusetts. Although these declines were evident among reported cases overall in Massachusetts during 2002--2006, an increase was observed among cases in the 15--24 year age group. In response to this increase, the Massachusetts Department of Public Health (MDPH) launched a surveillance initiative to collect more detailed information on cases reported during 2007--2009 among this younger age group and to examine the data for trends through 2009. This report describes results of both efforts, which revealed continued increases in rates of newly reported HCV infection among persons aged 15--24 years. These cases were reported from all areas of the state, occurred predominantly among non-Hispanic white persons, and were equally distributed among males and females. Of cases with available risk data, injection drug use (IDU) was the most common risk factor for HCV transmission. The increase in case reports appears to represent an epidemic of HCV infection related to IDU among new populations of adolescents and young adults in Massachusetts. The findings indicate the need for enhanced surveillance of HCV infection and intensified hepatitis C prevention efforts targeting adolescents and young adults.

Entities:  

Mesh:

Year:  2011        PMID: 21544042

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  81 in total

1.  Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline.

Authors:  Daniel John Smyth; Duncan Webster; Lisa Barrett; Mark MacMillan; Lisa McKnight; Frank Schweiger
Journal:  Can J Gastroenterol Hepatol       Date:  2014-11

2.  Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance.

Authors:  Rachel E Gicquelais; Betsy Foxman; Joseph Coyle; Marisa C Eisenberg
Journal:  Epidemics       Date:  2019-02-28       Impact factor: 4.396

3.  Will there be a vaccine to protect against the hepatitis C virus?

Authors:  Benoît Callendret; Christopher M Walker
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

4.  Editorial commentary: Hepatitis C virus testing and drug use in north america; is there more than meets the eye?

Authors:  Curt G Beckwith; Sarah Larney; Timothy P Flanigan
Journal:  Clin Infect Dis       Date:  2013-12-20       Impact factor: 9.079

5.  Hepatitis C virus serosorting in people who inject drugs: sorting out the details.

Authors:  Arthur Y Kim; Kimberly Page
Journal:  J Infect Dis       Date:  2013-10-16       Impact factor: 5.226

Review 6.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

7.  The opioid epidemic and injection drug use: MIPIE and health harms related to the injection of prescription opioids.

Authors:  Pedro Mateu-Gelabert; Honoria Guarino
Journal:  Int J Drug Policy       Date:  2018-04-05

8.  Integrating Routine HCV Testing in Primary Care: Lessons Learned from Five Federally Qualified Health Centers in Philadelphia, Pennsylvania, 2012-2014.

Authors:  Catelyn Coyle; Helena Kwakwa; Kendra Viner
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

9.  Social Network Diagramming as an Applied Tool for Public Health: Lessons Learned From an HCV Cluster.

Authors:  Katarina M Grande; Marisa Stanley; Carrie Redo; Amy Wergin; Sheila Guilfoyle; Mari Gasiorowicz
Journal:  Am J Public Health       Date:  2015-02-17       Impact factor: 9.308

10.  Reply to direct-acting antiviral drugs and hepatitis C virus: A therapeutic revolution?

Authors:  Darrick K Li; Raymond T Chung
Journal:  Cancer       Date:  2015-08-19       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.